Apoptosis vesicle derived from human umbilical cord mesenchymal stem cells as well as preparation method and antibacterial application of apoptosis vesicle

Through the preparation method of apoptotic vesicles of human umbilical cord mesenchymal stem cells, apoptotic vesicles were extracted using density gradient centrifugation technology, which solved the ineffectiveness of traditional antibiotics on multidrug-resistant bacteria, and achieved the methicillin-resistant golden grape Effective inhibition and killing of cocci and E. coli provides a safe and efficient novel antibacterial agent.

CN118956743APending Publication Date: 2024-11-15ANHUI MEDICAL UNIV
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411365960.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-29
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The long-term abuse of traditional antibiotics has led to the emergence of multidrug-resistant superbacterial bacteria. No effective new antibacterial agent has been found in the prior art, especially the treatment of common pathogens such as Staphylococcus aureus is difficult to effectively inhibit and kill bacteria.

Method used

Through the preparation method of apoptotic vesicles derived from human umbilical cord mesenchymal stem cells, apoptotic vesicles were extracted from the apoptosis supernatant by density gradient centrifugation technology, and apoptosis was induced by stagnant spores to obtain antibacterial Apoptotic vesicles that act as apoptotic vesicles used to inhibit and kill bacteria.

Benefits of technology

The prepared apoptotic vesicles can effectively inhibit and kill bacteria such as methicillin-resistant Staphylococcus aureus and E. coli, destroy bacterial biofilms, have high safety and immunogenicity, and are suitable as new antibacterial drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956743A_ABST
    Figure CN118956743A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of antibacterial drugs, in particular to apoptosis vesicles derived from human umbilical cord mesenchymal stem cells as well as a preparation method and antibacterial application of the apoptosis vesicles. The invention provides a preparation method of apoptosis vesicles derived from human umbilical cord mesenchymal stem cells, which comprises the following steps: culturing human umbilical cord mesenchymal stem cells in a culture medium containing staurosporine to obtain cell apoptosis supernate; and performing density gradient centrifugation on the cell apoptosis supernate to obtain the apoptosis vesicles. The apoptosis vesicles prepared by the invention are derived from human umbilical cord mesenchymal stem cells, and the immunogenicity of in-vivo transplantation is lower; bacteria can be inhibited and killed, and bacterial biofilms are destroyed; the MSC cryopreservation solution can be preserved at-80 DEG C, avoids inconvenience of cryopreservation resuscitation of MSC, can be used after being dissolved, is easy to master in use time, and provides technical support for treatment of bacterial infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of antibacterial drugs, and in particular to an apoptotic vesicle derived from human umbilical cord mesenchymal stem cells, a preparation method thereof and an antibacterial application thereof. Background Art

[0002] Bacterial infection remains one of the major killers endangering human health. Traditional antibiotics are currently the main treatment for bacterial infections. However, the long-term abuse or uncontrolled use of antibiotics has promoted the emergence of multidrug-resistant superbugs, which in turn threaten public health through the food chain. Pathogenic infections, including Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, etc., are also common factors and major causes of death in clinical delayed chronic wound healing. Therefore, actively exploring new antibacterial agents has important scientific significance and clinical application value.

[0003] Extracellular vesicles (EVs) are membrane vesicles with a lipid bilayer structure that are actively secreted or passively shed by cells. They are mainly divided into three categories: apoptotic vesicles (ApoVs), microvesicles, and small extracellular vesicles. Cells release a large number of ApoVs during apoptosis, which play a key role in the phagocytosis and clearance of apoptotic cells and can be used as natural therapeutic agents and drug delivery carriers. ApoVs derived from mesenchymal stem cells (MSCs) (MSC-ApoVs) have significant therapeutic effects in tissue regeneration and inflammation targeting. However, it is still unclear whether MSC-ApoVs have antibacterial effects. Summary of the invention

[0004] In order to solve the above problems, the present invention provides a human umbilical cord mesenchymal stem cell-derived apoptotic vesicle and its preparation method and antibacterial application. The apoptotic vesicle prepared by the present invention can effectively kill bacteria, inhibit and destroy bacterial biofilm.

[0005] In order to achieve the above object, the present invention provides the following technical solutions:

[0006] The present invention provides a method for preparing apoptotic vesicles derived from human umbilical cord mesenchymal stem cells, comprising the following steps:

[0007] Human umbilical cord mesenchymal stem cells were cultured in a medium containing staurosporine to obtain apoptotic supernatant;

[0008] The cell apoptosis supernatant is subjected to density gradient centrifugation to obtain apoptotic vesicles; the density gradient centrifugation comprises:

[0009] The cell apoptosis supernatant is subjected to a first centrifugation to obtain a first supernatant; the first centrifugation has a centrifugal force of 800 g and a time of 10 to 25 minutes;

[0010] The first supernatant is subjected to a second centrifugation to obtain a second supernatant; the second centrifugation has a centrifugal force of 2000 g and a time of 10 to 15 minutes;

[0011] The second supernatant is subjected to a third centrifugation to obtain a precipitate containing apoptotic vesicles; the centrifugal force of the third centrifugation is 16000g, and the time is 30 to 60 minutes.

[0012] Preferably, the density gradient centrifugation further comprises:

[0013] The precipitate containing the apoptotic vesicles is washed with sterile PBS and then centrifuged for the fourth time to collect the precipitate, which is the pure apoptotic vesicles; the centrifugal force of the fourth centrifugation is 16000g, and the time is 30 to 60 minutes.

[0014] Preferably, the temperatures of the first centrifugation, the second centrifugation, the third centrifugation and the fourth centrifugation are respectively 0-4°C.

[0015] Preferably, the concentration of staurosporine in the culture medium is 250 nM to 500 nM; the culture time is 6 h to 16 h; and the culture medium comprises: α-MEM complete culture medium.

[0016] Preferably, the culture medium further comprises fetal bovine serum with a volume concentration of 5% to 20%, wherein the fetal bovine serum is fetal bovine serum from which small extracellular vesicles have been removed.

[0017] The present invention provides apoptotic vesicles prepared by the preparation method of the above technical scheme, wherein the particle size of the apoptotic vesicles is 50-5000nm, the potential is a negative value, and the surface marker proteins include: CD9, TSG101, Calreticulin, β-actin and Caspase 3.

[0018] The present invention provides the use of the apoptotic vesicles described in the above technical solution in the preparation of antibacterial products, wherein the antibacterial products include products that inhibit bacterial growth and / or kill bacteria.

[0019] Preferably, the bacteria include: Methicillin-resistant Staphylococcus aureus and / or Escherichia coli.

[0020] The present invention provides an antibacterial drug, the active ingredients of which include the apoptotic vesicles described in the above technical solution and pharmaceutically acceptable excipients.

[0021] Preferably, the unit dose of the apoptotic vesicles in the antibacterial drug is ≥ 1.0×10 10 Particles / mL.

[0022] Beneficial effects:

[0023] The present invention provides a method for preparing apoptotic vesicles derived from human umbilical cord mesenchymal stem cells, comprising the following steps: culturing human umbilical cord mesenchymal stem cells in a culture medium containing staurosporine to obtain apoptotic supernatant; subjecting the apoptotic supernatant to density gradient centrifugation to obtain apoptotic vesicles. The apoptotic vesicles prepared by the present invention are derived from human umbilical cord mesenchymal stem cells, have lower immunogenicity and higher safety for in vivo transplantation, can inhibit and kill bacteria, and destroy bacterial biofilms; can be stored at -80°C, avoiding the inconvenience of MSC cryopreservation and thawing, can be used after thawing, and the use time is easy to control, providing technical support for the treatment of bacterial infections. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.

[0025] Figure 1 The results of apoptosis induction and detection of human umbilical cord mesenchymal stem cells in Example 1; wherein A is a schematic diagram of apoptosis induction of HucMSCs, B is the morphological characteristics of normal and apoptotic hucMSCs detected by inverted fluorescence microscopy, and C is the apoptosis of hucMSCs detected by flow cytometry after STS induction;

[0026] Figure 2 Schematic diagram of the method for extracting apoptotic vesicles from the apoptotic supernatant of HucMSCs;

[0027] Figure 3 The identification results of hucMSC-ApoVs; A is the hucMSC-ApoVs observed by transmission electron microscopy, B is the particle size result of hucMSC-ApoVs detected by NTA, C is the potential result of hucMSC-ApoVs detected by NTA, and D is the surface marker protein result of hucMSC-ApoVs detected by Western blot;

[0028] Figure 4 The experimental results of HucMSC-ApoVs inhibiting antibacterial growth and killing bacteria in Example 3; A and B are the scanning electron microscopy results after hucMSC-ApoVs or PBS treated MRSA and E.coli for 12 hours; C and D are the plate and colony count results after hucMSC-ApoVs or PBS incubated MRSA and E.coli for 4 hours; the arrows point to the shrunken, ruptured and dead bacteria;

[0029] Figure 5 The results of live / dead bacteria staining test after HucMSC-ApoVs and bacteria were co-incubated for 4 hours;

[0030] Figure 6 The experimental results show that HucMSC-ApoVs promotes the production of bacterial reactive oxygen species;

[0031] Figure 7 The results of bacterial membrane potential staining test after HucMSC-ApoVs and bacteria were co-incubated for 4 hours;

[0032] Figure 8 The figures are the test results of HucMSC-ApoVs inhibiting and destroying bacterial biofilm; A and C are the results of crystal violet staining and enzymatic quantitative analysis of biofilm in the test of HucMSC-ApoVs inhibiting bacterial biofilm formation; B and D are the results of crystal violet staining and enzymatic quantitative analysis of biofilm in the test of HucMSC-ApoVs destroying bacterial biofilm; E and F are the three-dimensional fluorescence images and fluorescence intensity results of the test of HucMSC-ApoVs inhibiting bacterial biofilm formation; G and H are the three-dimensional fluorescence images and fluorescence intensity results of the test of HucMSC-ApoVs destroying bacterial biofilm;

[0033] Among them, *** means p < 0.001, Live means living bacteria, and Dead means dead bacteria. DETAILED DESCRIPTION

[0034] The present invention provides a method for preparing apoptotic vesicles derived from human umbilical cord mesenchymal stem cells, comprising the following steps:

[0035] Human umbilical cord mesenchymal stem cells were cultured in a medium containing staurosporine to obtain apoptotic supernatant;

[0036] The cell apoptosis supernatant is subjected to density gradient centrifugation to obtain apoptotic vesicles; the density gradient centrifugation comprises:

[0037] The cell apoptosis supernatant is subjected to a first centrifugation to discard dead cells and obtain a first supernatant; the centrifugal force of the first centrifugation is 800g and the time is 10 to 25 minutes;

[0038] The first supernatant is subjected to a second centrifugation to discard the cell debris to obtain a second supernatant; the second centrifugation is performed at a centrifugal force of 2000 g for 10 to 15 minutes;

[0039] The second supernatant is subjected to a third centrifugation to obtain a precipitate containing apoptotic vesicles; the centrifugal force of the third centrifugation is 16000g, and the time is 30 to 60 minutes.

[0040] As a specific embodiment, the present invention cultured human umbilical cord mesenchymal stem cells in a complete culture medium for human umbilical cord mesenchymal stem cells until the cell density reached more than 90% to obtain more extracellular vesicles.

[0041] After obtaining human umbilical cord mesenchymal stem cells with a cell density of more than 90%, the present invention cultures the human umbilical cord mesenchymal stem cells in a culture medium containing staurosporine to obtain apoptosis supernatant. As a specific embodiment, the concentration of staurosporine in the culture medium can be 250nM, 300nM or 500nM, specifically 250nM; the culture time can be 6h to 16h, specifically 16h; the culture medium can be α-MEM complete culture medium; the culture medium can also contain fetal bovine serum with a volume concentration of 5% to 20%, specifically 10%, and the fetal bovine serum is fetal bovine serum with small extracellular vesicles removed. The present invention adds fetal bovine serum with small extracellular vesicles removed to the culture medium to eliminate the influence of the original extracellular vesicles in the fetal bovine serum on the experimental results.

[0042] After obtaining the cell apoptosis supernatant, the present invention performs density gradient centrifugation on the cell apoptosis supernatant to obtain apoptotic vesicles; the density gradient centrifugation includes: performing a first centrifugation on the cell apoptosis supernatant, discarding dead cells, and obtaining a first supernatant; the centrifugal force of the first centrifugation is 800g, and the time is 10-25min; performing a second centrifugation on the first supernatant, discarding cell debris, and obtaining a second supernatant; the centrifugal force of the second centrifugation is 2000g, and the time is 10-15min; performing a third centrifugation on the second supernatant to obtain a precipitate containing apoptotic vesicles; the centrifugal force of the third centrifugation is 16000g, and the time is 30-60min. As a specific embodiment, a precipitate containing apoptotic vesicles is obtained, and the present invention washes the precipitate containing apoptotic vesicles with sterile PBS and then performs a fourth centrifugation to collect the precipitate, which is a pure apoptotic vesicle; the centrifugal force of the fourth centrifugation is 16000g, and the time can be 30-60min, specifically 30min. As a specific embodiment, the first centrifugation time is 10 minutes, the second centrifugation time is 10 minutes, and the third centrifugation time is 30 minutes; the temperatures of the first centrifugation, the second centrifugation, the third centrifugation and the fourth centrifugation are 0 to 4°C, specifically 4°C.

[0043] The human umbilical cord mesenchymal stem cell-derived apoptotic vesicles prepared by the present invention can effectively kill bacteria, inhibit and destroy bacterial biofilms, promote bacterial reactive oxygen production, can be stored for a long time in a -80°C ultra-low temperature refrigerator and maintain biological activity, and have excellent clinical transformation and application value.

[0044] The present invention also provides apoptotic vesicles prepared by the method described in the above technical solution, wherein the particle size of the apoptotic vesicles is 50-5000nm, the potential is a negative value, and the surface marker proteins include: CD9, TSG101, Calreticulin, β-actin and Caspase 3.

[0045] Based on the above advantages, the present invention also provides the use of the apoptotic vesicles described in the above technical solution in the preparation of antibacterial products, wherein the antibacterial products include products that inhibit bacterial growth and / or kill bacteria.

[0046] As a specific example, the bacteria may be: Methicillin-resistant Staphylococcus arueus and / or Escherichia coli.

[0047] Based on the above advantages, the present invention also provides an antibacterial drug, the active ingredients of which include the apoptotic vesicles described in the above technical solution and pharmaceutically acceptable excipients.

[0048] As a specific example, the unit dose of the apoptotic vesicles in the antibacterial drug is ≥ 1.0×10 10 particles / mL, specifically 1.0×10 10 The unit dose of the present invention is the effective unit dose concentration of the antibacterial drug that can kill bacteria.

[0049] To further illustrate the present invention, the apoptotic vesicles derived from human umbilical cord mesenchymal stem cells and their preparation method and antibacterial application provided by the present invention are described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.

[0050] Example 1 Induction and detection of apoptosis of human umbilical cord mesenchymal stem cells

[0051] The main materials and sources used are as follows:

[0052] MSC culture reagents (Guangzhou Saiye Biotechnology Co., Ltd.), fetal bovine serum (Gibco), trypsin (Shanghai Biyuntian Biotechnology Co., Ltd.), antibiotics (Shanghai Biyuntian Biotechnology Co., Ltd.), carbon dioxide incubator (Forma); staurosporine (MCE), Annexin V-FITC apoptosis detection kit (Shanghai Biyuntian Biotechnology Co., Ltd.), human umbilical cord mesenchymal stem cells (HucMSCs) were purchased from Saiye (Guangzhou) Biotechnology Co., Ltd., with the catalog number #HUXUC-01001, and human umbilical cord mesenchymal stem cell complete culture medium (#HUXUC-90011, ).

[0053] HucMSCs-induced apoptosis and detection:

[0054] 1. Use human umbilical cord mesenchymal stem cell complete medium to culture HucMSCs to a cell density of more than 90% under the following conditions: 37°C, 5% CO 2 ; Centrifuge the fetal bovine serum for 16 h at 100,000×g at 4° C. using a Beckman ultracentrifuge, collect the supernatant to obtain fetal bovine serum without small extracellular vesicles; Add fetal bovine serum without small extracellular vesicles to α-MEM complete medium at a final volume concentration of 10% to obtain a complete medium without small extracellular vesicles;

[0055] 2. HucMSCs were cultured with 250 nM staurosporine (STS) in complete culture medium without small extracellular vesicles for 16 h to induce apoptosis of hucMSCs, which was recorded as the experimental group (STS); a control group without staurosporine (Ctrl) was also set up.

[0056] 3. Inverted fluorescence microscopy was used to observe the cell morphology changes in the experimental group and the control group, and flow cytometry was used to detect cell apoptosis. Figure 1 .

[0057] Depend on Figure 1 It can be seen that the apoptotic hucMSCs became smaller in size, shrunken in morphology, and shed cells. The number of apoptotic cells increased significantly after induction by staurosporine, which can obviously induce cell apoptosis.

[0058] Example 2 Extraction and identification of apoptotic vesicles derived from human umbilical cord mesenchymal stem cells

[0059] The main materials and sources used are as follows: CD9 antibody (BOSTER), TSG101 antibody (BOSTER), Calreticulin antibody (BOSTER), β-actin antibody (BOSTER), Syntenin-1 antibody (BOSTER), Caspase 3 (CST), horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG secondary antibody (Thermo Fisher Scientific, USA), premixed HRP chemiluminescent substrate (Millipore, USA); transmission electron microscope (FEI Tecnai 12, Philips); nanoparticle tracking analyzer (ZetaView, Germany).

[0060] (1) The preparation process of umbilical cord mesenchymal stem cell-derived apoptotic vesicles (hucMSC-ApoVs) is as follows Figure 2 As shown, the details are as follows:

[0061] The hucMSCs were subjected to apoptosis treatment by the method of the experimental group in Example 1, and the hucMSCs apoptosis supernatant was collected; the collected hucMSCs apoptosis supernatant was centrifuged at 4°C and 800×g for 10 min by density gradient centrifugation to remove dead cells; after the supernatant was collected, it was centrifuged at 4°C and 2000×g for 10 min to remove cell debris; after the supernatant was collected, it was centrifuged at 4°C and 16000×g for 30 min; after the supernatant was discarded, sterile PBS was added and centrifuged at 4°C and 16000×g for 30 min, washed once, and the precipitate was collected; the precipitate was resuspended with an appropriate amount of sterile PBS, stored at -80°C after aliquoting, and protein quantitative detection was performed using a BCA protein quantitative kit method, and the detection concentration was 1.0μg / μl.

[0062] (2) Observation of the basic morphology of hucMSC-ApoVs by transmission electron microscopy: 20 μL of hucMSC-ApoVs prepared in step (1) was taken, mixed thoroughly, and then dropped onto a 2 mm diameter sample-carrying copper mesh. After standing at room temperature for 5 min, the residual liquid at the edge of the copper mesh was gently absorbed with filter paper. The copper mesh was then inverted on a drop of 30 g / L phosphotungstic acid (pH 6.8) and negatively stained at room temperature for 5 min. Finally, the copper mesh was dried under an incandescent lamp, observed under a transmission electron microscope, and photographed. The results are shown in FIG. Figure 3 As shown in A, hucMSC-ApoVs showed a typical "cup-shaped" structure.

[0063] (3) NTA detection of hucMSC-ApoVs particle size, concentration and potential: 2 μL of hucMSC-ApoVs was diluted (1:1000) and then tested on NTA. Figure 3 As shown in Figure B, the particle size distribution of hucMSC-ApoVs is between 50 and 5000 nm, with a peak value of about 246.8 nm. Figure 3 As shown in C, the potential of hucMSC-ApoVs is negative.

[0064] (4) Western blot detection of surface marker proteins of hucMSC-ApoVs: 12% SDS-PAGE electrophoresis gel was prepared, and the apoptotic vesicles extracted in step (1) were fully lysed and added with 1 / 4 volume of 5×SDS loading buffer, boiled for 10 min, and 200 μg of protein was loaded. The protein was transferred to a PVDF membrane by electrotransfer (400 mA, 90 min), and blocked with TBS / T containing 50 g / L skim milk at room temperature for 1 h. The membrane was reacted with CD9, TSG101, Calreticulin, β-actin, Syntenin-1, and Caspase 3 antibodies (1:500) at 4°C overnight, and the membrane was stained with 0.1% Tween-containing solution the next day. After washing the membrane three times with TBST buffer containing 0.20%, incubating with HRP-labeled goat anti-rabbit IgG secondary antibody at 37°C for 1 hour, washing the membrane three times with TBST buffer containing 0.5% Tween20, adding premixed HRP chemiluminescent substrate, and detecting by chemiluminescent gel imaging system, the results are shown in Figure 3 As shown in D, hucMSC-ApoVs protein-specific markers CD9, TSG101, Calreticulin, β-actin, and Caspase 3 were positively expressed, while Syntenin-1 was negatively expressed.

[0065] Example 3 HucMSC-ApoVs inhibits bacterial growth and kills bacteria

[0066] Methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli) strains were extracted from frozen glycerol, revived from the stored strains, inoculated into Luria-Bertani (LB) medium, shaken on a 37°C constant temperature shaker overnight, and the absorbance of the bacterial solution was measured at 600 nm to determine the bacterial concentration; the methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli) strains are disclosed in the literature [Wang W, Cui Y, Wei X, et al. CuCo 2 O 4Nanoflowerswith Multiple Enzyme Activities for Treating Bacterium-Infected Wounds viaCuproptosis-like Death.ACS Nano.2024;18(24):15845-15863.]and【HuZ,Shan J,JinX,et al.Nanoarchitectonics of in Situ Antibiotic-Releasing Acicular Nanozymes for Targeting and Inducing Cuproptosis-like Death to Eliminate Drug-ResistantBacteria.ACS Nano.2024;18(35):24327-24349.].

[0067] 1. In the antibacterial experiment, MRSA or E. coli were divided into PBS group and hucMSC-ApoVs group. The concentrations of bacteria and hucMSC-ApoVs were 1.0×10 6 CFU / mL and 1.0×10 10 particles / mL, the solution volume was 200 μL. After incubation for 4 h, the colonies were cultured and counted by the plate spreading method. Figure 4 As shown in C and D. The results show that hucMSC-ApoVs inhibited the growth of MRSA and E.coli.

[0068] 2. Using the method in step 1, incubate MRSA and E.coli with hucMSC-ApoVs or PBS for 12 hours, and then fix the bacteria with 2.5% glutaraldehyde. Place the bacteria in ethanol solutions of different concentrations, namely 10%, 30% v / v, 50% v / v, 70% v / v, and 90% v / v. After each resuspension, resuspend the bacteria repeatedly in ethanol solutions of the same concentration, dehydrate for 10 minutes, and disperse the bacterial samples in 200 μL ethanol for characterization using a scanning electron microscope. Figure 4 As shown in A and B, hucMSC-ApoVs treatment promoted the shrinkage, rupture and death of bacteria.

[0069] Example 4 HucMSC-ApoVs promote bacterial death

[0070] The antibacterial experimental method described in step 1 of Example 3 was used. After HucMSC-ApoVs and bacteria were co-incubated for 4 hours, a live / dead bacteria staining test was performed. The bacterial suspension was labeled using a live / dead bacteria activity kit containing PI and SYTO9. After different treatments, the bacteria were stained with PI and SYTO9 fluorescent nucleic acid and incubated in the dark for 25 minutes. The bacteria were then rinsed three times and suspended in a 0.9% saline solution. Live bacteria (green fluorescence) and dead bacteria (red fluorescence) were observed using a laser scanning microscope (CSIM-130). The results are shown in the figure. Figure 5 As shown, hucMSC-ApoVs can promote bacterial death.

[0071] Example 5 HucMSC-ApoVs promotes bacterial reactive oxygen production

[0072] DCFH-DA ROS fluorescent probe (concentration of 10 mM) was diluted with LB medium at a volume ratio of 1:2000. 6 CFU / mL) were inoculated in a confocal culture dish, and various bacteria treated for 4 hours were added (the treatment method was the same as step 1 in Example 3). The culture medium was removed and 1 mL of diluted DCFH-DA was added. Incubated in an incubator for 20 minutes and washed three times with PBS culture medium. Fluorescence was photographed using a laser confocal microscope to observe the green fluorescence intensity (CSIM-130). The results are shown in Figure 6 As shown, hucMSC-ApoVs can promote bacterial reactive oxygen species production.

[0073] Example 6 HucMSC-ApoVs disrupts bacterial cell membrane

[0074] The antibacterial experimental method described in step 1 of Example 3 was used to perform a bacterial membrane potential staining test after HucMSC-ApoVs and bacteria were co-incubated for 4 hours. After different treatments, the bacterial suspension was labeled and stained with DiSC3(5) and incubated in the dark for 25 minutes. The bacteria were then rinsed three times and suspended in a 0.9% saline solution. A laser scanning microscope (CSIM-13) was used to observe changes in bacterial membrane potential. The results are shown in Figure 2. Figure 7 As shown, hucMSC-ApoVs can promote the disruption of bacterial cell membrane potential.

[0075] Example 7 HucMSC-ApoVs inhibit and destroy bacterial biofilm

[0076] (1) HucMSC-ApoVs inhibited bacterial biofilm formation: 500 μL of bacteria and 1.5 mL of LB medium (purchased from Beijing Solebow Technology Co., Ltd.) were added to a 24-well plate; the bacteria were MRSA or E. coli in Example 3, with a concentration of 1.0×10 6CFU / mLh. A certain amount of hucMSC-ApoVs was added to the wells of the hucMSC-ApoVs group, and the same dose of PBS was added to the PBS group. The concentration of hucMSC-ApoVs was 1.0×10 10 Particles / mL. Incubate at 37℃ for 72h. After incubation, remove the supernatant and wash the bottom biofilm three times with PBS. Use crystal violet staining and enzymatic quantitative analysis of the biofilm. For specific methods, see: [Mei J, Xu D, Wang L, et al. Biofilm Microenvironment-Responsive Self-Assembly Nanoreactorsfor All-Stage Biofilm Associated Infection through Bacterial Cuproptosis-likeDeath and Macrophage Re-Rousing. Adv Mater. 2023; 35(36): e2303432.], the results are as follows Figure 8 As shown in A and C. The two groups were stained with SYTO-9 and PI for 30 min at room temperature, and three-dimensional fluorescence images were obtained under a laser confocal microscope (CSIM-130). Figure 8 As shown in E and F. The results show that hucMSC-ApoVs can significantly inhibit the formation of bacterial biofilm.

[0077] (2) HucMSC-ApoVs destroy bacterial biofilm: the concentration of 1.0×10 8 500 μL of bacteria with CFU / mL and 1.5 mL of broth were added to a 24-well plate and incubated at 37°C for 48 h to form a complete biofilm; the bacteria were MRSA or E. coli in Example 3. In the hucMSC-ApoVs group, a certain amount of hucMSC-ApoVs was added to the wells, and the same dose of PBS was added to the PBS group. The concentration of hucMSC-ApoVs was 1.0×10 10 particles / mL. Incubate at 37℃ for 24h. After incubation, remove the supernatant and wash the bottom biofilm three times with PBS. Use crystal violet staining and enzymatic quantitative analysis of biofilm, such as Figure 8 As shown in B and D. The two groups were stained with SYTO-9 and PI for 30 min at room temperature, and three-dimensional fluorescence images were obtained under a laser confocal microscope (CSIM-130). Figure 8 As shown in G and H. The results show that hucMSC-ApoVs can significantly destroy bacterial biofilm.

[0078] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A method for preparing apoptotic vesicles derived from human umbilical cord mesenchymal stem cells, characterized in that: The following steps are involved: Human umbilical cord mesenchymal stem cells were cultured in a medium containing staurosporine to obtain apoptotic supernatant; The cell apoptosis supernatant is subjected to density gradient centrifugation to obtain apoptotic vesicles; the density gradient centrifugation comprises: The cell apoptosis supernatant is subjected to a first centrifugation to obtain a first supernatant; the centrifugal force of the first centrifugation is 800g, and the time is 10 to 25 minutes; The first supernatant is subjected to a second centrifugation to obtain a second supernatant; the second centrifugation has a centrifugal force of 2000 g and a time of 10 to 15 minutes; The second supernatant is subjected to a third centrifugation to obtain a precipitate containing apoptotic vesicles; the centrifugal force of the third centrifugation is 16000g, and the time is 30 to 60 minutes.

2. The preparation method according to claim 1, characterized in that: The density gradient centrifugation also includes: The precipitate containing the apoptotic vesicles is washed with sterile PBS and then centrifuged for the fourth time to collect the precipitate, which is the pure apoptotic vesicles; the centrifugal force of the fourth centrifugation is 16000g, and the time is 30 to 60 minutes.

3. The preparation method according to claim 1 or 2, characterized in that: The temperatures of the first centrifugation, the second centrifugation, the third centrifugation and the fourth centrifugation are 0-4°C respectively.

4. The preparation method according to claim 1, characterized in that: The concentration of staurosporine in the culture medium is 250nM to 500nM; the culture time is 6h to 16h; and the culture medium includes: α-MEM complete culture medium.

5. The preparation method according to claim 1 or 4, characterized in that: The culture medium also includes fetal bovine serum with a volume concentration of 5% to 20%, wherein the fetal bovine serum is fetal bovine serum from which small extracellular vesicles have been removed.

6. The apoptotic vesicle prepared by the preparation method according to any one of claims 1 to 5, characterized in that: The apoptotic vesicle has a particle size of 50 to 5000 nm, a negative potential, and surface marker proteins including CD9, TSG101, Calreticulin, β-actin and Caspase 3.

7. Use of the apoptotic vesicles according to claim 6 in the preparation of antibacterial products, wherein the antibacterial products include products that inhibit bacterial growth and / or kill bacteria.

8. The use according to claim 7, characterized in that: The bacteria include: Methicillin-resistant Staphylococcus aureus and / or Escherichia coli.

9. An antibacterial drug, characterized in that: The effective ingredients include the apoptotic vesicles according to claim 6 and pharmaceutically acceptable excipients.

10. The antibacterial drug according to claim 9, characterized in that: The unit dose of the apoptotic vesicles in the antibacterial drug is ≥ 1.0×10 10 Particles / mL.

Citation Information

Cited By

  • Ruthenium-dihydromyricetin, ruthenium-dihydromyricetin-loaded apoptosis vesicle as well as preparation method and application of ruthenium-dihydromyricetin-loaded apoptosis vesicle

    CN119661490A

  • A ruthenium-dihydromyricetin, an apoptosis vesicle loaded with ruthenium-dihydromyricetin, and a preparation method and application thereof

    CN119661490B

  • Application of mesenchymal stem cell apoptosis vesicles in preparation of medicine for treating dry eye

    CN120093785A